Sponsor:
Mayo Clinic
Code:
NCT07570940
Conditions
Coronary Artery Disease
Atrial Fibrillation
Eligibility Criteria
Sex: All
Age: 40+
Healthy Volunteers: Not accepted
Interventions
Liposomal bupivacaine
Placebo
Brief summary:
Conditions
Coronary Artery Disease
Atrial Fibrillation
Study ID
NCT07570940
Start date
Sep 29, 2026
Status verified date
Nov, 2026
Completion date
Sep, 2030
Anticipated
Primary completion date
Sep, 2030
Anticipated
Eligibility Criteria
Sex: All
Age: 40+
Healthy Volunteers: Not accepted
Enrollment
450 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: Stellate ganglion block using liposomal bupivacaine
placebo comparator: Sham block using saline placebo
Interventions
Liposomal bupivacaine
Placebo
Primary outcome measure
Central contacts
Locations
Mayo Clinic in Rochester
Recruiting
Rochester, Minnesota, United States, 55905
Contacts
ACRU Study Team
866-265-9263Principal Investigator:
Juan G. Ripoll Sanz, MD
Sponsor
Mayo Clinic
Last update posted
Nov 19, 2026
Last verified
Nov, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by Mayo Clinic on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.